Publications

  1. Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, Diaz-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. Eur J Cancer. 2024 Aug; 207:114160 Epub 2024 June 10
    View PubMed
  2. Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, Andre T, de Gramont A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024 Mar; 199:113537 Epub 2024 Jan 15
    View PubMed
  3. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers (Basel). 2023 Aug 15; 15 (16)
    View PubMed
  4. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Eur J Cancer. 2023 Jan; 178:162-170 Epub 2022 Nov 02
    View PubMed
  5. Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andre T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 Jun 13; 114 (6):819-828
    View PubMed
  6. McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll HJ, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectr. 2022 Mar 2; 6 (2)
    View PubMed
  7. Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer >/= 70 years. Eur J Cancer. 2022 Mar; 163:1-15 Epub 2022 Jan 13
    View PubMed
  8. Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022 Jan 11; 114 (1):60-67
    View PubMed
  9. Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 Nov 29; 113 (12):1705-1713
    View PubMed
  10. Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021 Nov; 6 (11):933-946 Epub 2021 Sept 08
    View PubMed
  11. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, Vanderwalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Aug 15; 27 (16):4587-4598 Epub 2021 June 11
    View PubMed
  12. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 Jul; 26 (7):610-618 Epub 2021 Mar 06
    View PubMed
  13. Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 Apr 6; 325 (13):1277-1286
    View PubMed
  14. Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. J Natl Cancer Inst. 2021 Apr 6; 113 (4):400-407
    View PubMed
  15. Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, Grothey A, Somer BG, Dickson PV. Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Ann Surg Oncol. 2021 Mar; 28 (3):1417-1427 Epub 2020 Aug 27
    View PubMed
  16. Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, Yamanaka T, Boukovinas I, Hollander NH, Galli F, Yamazaki K, Georgoulias V, Kerr R, Oki E, Lonardi S, Harkin A, Rosati G, Paul J. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. J Clin Oncol. 2021 Feb 20; 39 (6):631-641 Epub 2021 Jan 13
    View PubMed
  17. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andre T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 Feb 20; 39 (6):642-651 Epub 2020 Dec 23
    View PubMed
  18. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021 Feb 1; 273 (2):341-349
    View PubMed
  19. Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021; 13:17588359211020547 Epub 2021 June 30
    View PubMed
  20. Andre T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020 Dec; 21 (12):1620-1629
    View PubMed
  21. Sobrero AF, Puccini A, Shi Q, Grothey A, Andre T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, Bruzzi P. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020 Oct; 138:182-188 Epub 2020 Sept 03
    View PubMed
  22. Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, Dickson PV, Glazer ES, Yakoub D, Shibata D, Grothey AF, Philip PA, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ, Deneve JL. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. J Surg Oncol. 2020 Jun; 121 (8):1320-1328 Epub 2020 Mar 12
    View PubMed
  23. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, Andre T, ACCENT Group. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 May; 130:63-71 Epub 2020 Mar 12
    View PubMed
  24. Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr; 31 (4):480-486 Epub 2020 Jan 16
    View PubMed
  25. An MW, Tang J, Grothey A, Sargent DJ, Ou FS, Mandrekar SJ. Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemp Clin Trials Commun. 2020 Mar; 17:100492 Epub 2019 Nov 22
    View PubMed
  26. Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol. 2020; 12:1758835920910913 Epub 2020 Mar 06
    View PubMed
  27. McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020 Jan; 20 (1):101-109 Epub 2019 Nov 21
    View PubMed
  28. Grothey A, Bekaii-Saab TS, Yoshino T, Prager GW. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2020 Jan; 18 Suppl 2 (1):1-24
    View PubMed
  29. Grothey A, Prager GW, Yoshino T, Bekaii-Saab TS. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussion. Clin Adv Hematol Oncol. 2020 Jan; 18 Suppl 2 (1):21-23
    View PubMed
  30. Vera J, Paludo J, Kottschade L, Brandt J, Yan Y, Block M, McWilliams R, Dronca R, Loprinzi C, Grothey A, Markovic SN. Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. Support Care Cancer. 2019 Oct; 27 (10):3869-3875 Epub 2019 Feb 14
    View PubMed
  31. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep; 30 (9):1466-1471 Epub 2019 Dec 12
    View PubMed
  32. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep 1; 30 (9):1466-1471
    View PubMed
  33. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug; 20 (8):1070-1082 Epub 2019 June 28
    View PubMed
  34. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Jul 1; 5 (7):1008-1019
    View PubMed
  35. Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D(3) levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30 (7):757-765 Epub 2019 May 18
    View PubMed
  36. Grothey A, Yaeger R, Paez D, Tabernero J, Taieb J, Yoshino T, Groc M, Vedovato J, Chetaille E, Van Cutsem E. ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Ann Oncol. 2019 Jul; 30 Suppl 4:iv109 Epub 2019 Dec 04
    View PubMed
  37. Salem M, Juckett L, Schrock A, Ross J, Puccini A, Grothey A, Lee J, Miller V, Madison R, Ali S. Landscape of FMS-like tyrosine kinase 3 (FLT3) and associated molecular alterations in 44,766 gastrointestinal (GI) cancers. Ann Oncol. 2019 Jul; 30 Suppl 4:iv129 Epub 2019 Dec 04
    View PubMed
  38. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, Garcia Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv154 Epub 2019 Dec 04
    View PubMed
  39. Ploeger B, Hoefman S, Ruppert M, Vis P, Zisowsky J, Grothey A, Van Cutsem E, Dochy E, Cleton A. Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction. Ann Oncol. 2019 Jul; 30 Suppl 4:iv90 Epub 2019 Dec 04
    View PubMed
  40. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, Garcia Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer Annals of Oncology. 2019 Jul 1; 30:iv154
  41. Chakrabarti S, Sara J, Lobo R, Eiring R, Finnes H, Mitchell J, Hartgers M, Okano A, Halfdanarson T, Grothey A. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clin Colorectal Cancer. 2019 Mar; 18 (1):52-57 Epub 2018 Oct 10
    View PubMed
  42. Grothey A, Marshall JL, Bekaii-Saab T. Sequencing beyond the second-line setting in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2019 Mar; 17 Suppl 7 (3):1-19
    View PubMed
  43. Grothey A, Marshall JL, Bekaii-Saab T. Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations. Clin Adv Hematol Oncol. 2019 Mar; 17 Suppl 7 (3):16-18
    View PubMed
  44. Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, Andre T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019 Feb; 24 (2):185-192 Epub 2018 Sept 06
    View PubMed
  45. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, Cheung M, Best R, Cheung D, Huang R, Barros-Gomes S, Pitz M, Singal PK, Jassal DS, Mulvagh SL. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb; 32 (2):267-276 Epub 2018 Nov 17
    View PubMed
  46. Wang CB, Shahjehan F, Merchea A, Li Z, Bekaii-Saab TS, Grothey A, Colibaseanu DT, Kasi PM. Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Front Oncol. 2019; 9:76 Epub 2019 Feb 19
    View PubMed
  47. Yoshino T, Portnoy DC, Obermannova R, Bodoky G, Prausova J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 2019 Jan 1; 30 (1):124-131
    View PubMed
  48. Wang Y, Jones JC, Jones JC, Kipp BR, Grothey A. Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer. Ann Oncol 2019 Jan 1; 30 (1):147-149
    View PubMed
  49. Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. Br J Cancer. 2018 Dec; 119 (12):1451-1455 Epub 2018 Nov 29
    View PubMed
  50. Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018 Dec; 82 (6):961-969 Epub 2018 Oct 22
    View PubMed
  51. Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018 Nov; 103:205-213 Epub 2018 Sept 27
    View PubMed
  52. Salem ME, Puccini A, Grothey A, Xiu J, Goldberg R, Kim ES, Korn WM, Lenz HJ, Raghavan D, Marshall JL, Hall MJ. Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low. Ann Oncol. 2018 Oct; 29 Suppl 8:viii650-viii651
    View PubMed
  53. Rich TA, Clifton K, Grothey A, Hendifar A, Henry DH, Kagawa Y, Nakamura Y, Okamoto W, Tan BR, Sherrill G, Yoshino T, Raymond VM, Shiotsu Y, Lanman RB, Morris V. RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer. Ann Oncol. 2018 Oct; 29 Suppl 8:viii162
    View PubMed
  54. Goey KKH, Sorbye H, Glimelius B, Adams RA, Andre T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Diaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 Sep; 100:35-45 Epub 2018 June 22
    View PubMed
  55. Jin Z, Sanhueza CT, Johnson B, Nagorney DM, Larson DW, Mara KC, Harmsen WC, Smyrk TC, Grothey A, Hubbard JM. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2018 Sep; 23 (9):1083-1091 Epub 2018 Apr 19
    View PubMed
  56. Shi Q, Paul J, Grothey A. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018 Jul 26; 379 (4):396-397
    View PubMed
  57. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Jul; 16 (7):852-871
    View PubMed
  58. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Jul; 16 (7):874-901
    View PubMed
  59. Taylor G, Karlin N, Halfdanarson TR, Coppola K, Grothey A. Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clin Colorectal Cancer. 2018 Jun; 17 (2):e183-e187 Epub 2017 Nov 21
    View PubMed
  60. Johnson B, Jin Z, Haddock MG, Hallemeier CL, Martenson JA, Smoot RL, Larson DW, Dozois EJ, Nagorney DM, Grothey A. A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. Oncologist. 2018 Jun; 23 (6):679-685 Epub 2018 Feb 14
    View PubMed
  61. Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol. 2018 Jun; 144 (6):1197-1204 Epub 2018 Apr 11
    View PubMed
  62. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105 Epub 2020 Jan 07
    View PubMed
  63. Salem M, Grothey A, Goldberg R, Xiu J, Korn W, Shields A, Hwang J, Philip P, Lenz H, Marshall J. Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors. Ann Oncol. 2018 Jun; 29 Suppl 5:v109 Epub 2020 Jan 07
    View PubMed
  64. Van Cutsem E, Cuyle P, Huijberts S, Schellens J, Elez E, Yaeger R, Fakih M, Montagut C, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan H, Maharry K, Christy-Bittel J, Gollerkeri A, Kopetz S, Grothey A, Tabernero J. BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Ann Oncol. 2018 Jun; 29 Suppl 5:v109 Epub 2020 Jan 07
    View PubMed
  65. Yoshino T, Siena S, Dalal R, Okuda Y, Yamamoto E, Grothey A. A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress. Ann Oncol. 2018 Jun; 29 Suppl 5:v83 Epub 2020 Jan 07
    View PubMed
  66. Shah M, Grothey A, Tebbutt N, Xu R, Yoshino T, Cervantes A, Tabernero J, Taieb J, Falcone A, Xu B, Fontaine M, Borodyansky L, Van Cutsem E. CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress. Ann Oncol. 2018 Jun; 29 Suppl 5:v84 Epub 2020 Jan 07
    View PubMed
  67. Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Mol Cancer Res. 2018 May; 16 (5):805-812 Epub 2018 Mar 09
    View PubMed
  68. Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? Ann Oncol. 2018 May 1; 29 (5):1099-1107
    View PubMed
  69. Grothey A, Venook AP. Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. J Natl Compr Canc Netw. 2018 May; 16 (5S):611-615
    View PubMed
  70. Kasi PM, Grothey A. Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. Drugs. 2018 May; 78 (7):737-745
    View PubMed
  71. Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018 Apr; 16 (4):359-369
    View PubMed
  72. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018 Mar 29; 378 (13):1177-1188
    View PubMed
  73. Grothey A. Highlights in metastatic colorectal cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. Clin Adv Hematol Oncol. 2018 Mar; 16 Suppl 6 (3):20-23
    View PubMed
  74. Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA Jr. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res. 2018 Jan 15; 24 (2):316-325 Epub 2017 Oct 30
    View PubMed
  75. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018; 10:1758835918780140 Epub 2018 June 18
    View PubMed
  76. Grothey A, Yoshino T, Bodoky G, Ciuleanu T, Garcia-Carbonero R, Garcia-Alfonso P, Van Cutsem E, Muro K, Mytelka DS, Li L, Lipkovich O, Hsu Y, Sashegyi A, Ferry D, Nasroulah F, Tabernero J. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open. 2018; 3 (3):e000347 Epub 2018 Apr 24
    View PubMed
  77. Major-Elechi BT, Novotny PJ, Singh JA, Bonner JA, Dueck AC, Sargent DJ, Grothey A, Sloan JA. Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). Int J Stat Med Res. 2018; 7 (4):137-146 Epub 2018 Nov 16
    View PubMed
  78. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018 Jan 1; 29 (1):44-70
    View PubMed
  79. Johnson B, Jin Z, Truty MJ, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Grothey A. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2018 Jan; 23 (1):128-134 Epub 2017 Sept 13
    View PubMed
  80. McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2018 Jan; 9 (1):24-31 Epub 2017 Sept 13
    View PubMed
  81. Ahn DH, Grothey A. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncol 2017 Nov; 18 (11):1427-1428 Epub 2017 Sept 25
    View PubMed
  82. Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct; 92 (10):1004-1010 Epub 2017 Aug 17
    View PubMed
  83. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. (Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35 (23):2624-2630 Epub 2017 May 09
    View PubMed
  84. Nelson H, Machairas N, Grothey A. Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. JAMA Oncol. 2017 Jul 1; 3 (7):885-886
    View PubMed
  85. Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs. 2017 Jul; 77 (10):1091-1103
    View PubMed
  86. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ, ARCAD Clinical Trials Program. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database. J Clin Oncol. 2017 Jun 10; 35 (17):1929-1937 Epub 2017 Apr 17
    View PubMed
  87. Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun; 16 (2):124-128 Epub 2016 Sept 17
    View PubMed
  88. Grothey A, Shah M, Yoshino T, Van Cutsem E, Taieb J, Xu R, Tebbutt NC, Falcone A, Cervantes A, Borodyansky L, Li CJ, other CanStem303 Investigators. Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. Ann Oncol. 2017 Jun; 28 Suppl 3:iii135-iii136
    View PubMed
  89. Bendell J, Hubbard J, O'Neil BH, Jonker D, Starodub A, Peyton J, Pitot H, Halfdanarson T, Nadeau B, Zubkus J, Adesunloye B, Edenfield J, Li YZ, Li W, Grothey A, Borodyansky L, Li CJ. Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Ann Oncol. 2017 Jun; 28 Suppl 3:iii150-iii151
    View PubMed
  90. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Mar; 15(3):370-398.
    View PubMed
  91. Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol. 2017 Feb; 9 (2):106-126 Epub 2016 Nov 10
    View PubMed
  92. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  93. Gonzalez JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, Grothey A. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res. 2017; 9:149-158 Epub 2017 Apr 27
    View PubMed
  94. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A, Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016 Dec; 17 (12):1709-1719 Epub 2016 Oct 12
    View PubMed
  95. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 Dec; 21 (12):1509-1521 Epub 2016 Nov 23
    View PubMed
  96. Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016 Dec; 24 (12):5059-5068 Epub 2016 Aug 18
    View PubMed
  97. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (arcad) database Lancet Oncology. 2016 Dec; 17: (12)1709-19.
  98. Mahipal A, Grothey A. Role of Biologics in First-Line Treatment of Colorectal Cancer. J Oncol Pract. 2016 Dec; 12 (12):1219-1228
    View PubMed
  99. Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist. 2016 Nov; 21 (11):1306-1314 Epub 2016 Sept 28
    View PubMed
  100. Grothey A, Sargent DJ. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine. JAMA Oncol 2016 Sep 1; 2 (9):1133-4
    View PubMed
  101. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug; 27 (8):1386-422 Epub 2016 July 05
    View PubMed
  102. Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016 Jul 13; 16:467 Epub 2016 July 13
    View PubMed
  103. Grothey A, Ellis LM. Therapy: Colorectal cancer: how to teach an old drug new tricks. Nat Rev Gastroenterol Hepatol 2016 Jul; 13 (7):384-5 Epub 2016 May 25
    View PubMed
  104. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016 May; 17 (5):663-70 Epub 2016 Apr 12
    View PubMed
  105. Kasi PM, Grothey A. Chemotherapy Maintenance. Cancer J. 2016 May-Jun; 22: (3)199-204.
    View PubMed
  106. Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10; 34 (11):1182-9 Epub 2016 Feb 08
    View PubMed
  107. Grothey A, Marshall JL, Seery TE. Current Options for Third-Line Treatment of Metastatic Colorectal Cancer. Clin Adv Hematol Oncol. 2016 Mar; 14 (3 Suppl 3):1-15
    View PubMed
  108. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
  109. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016 Mar; 24 (3):1071-8 Epub 2015 Aug 08
    View PubMed
  110. Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs. 2016 Feb; 34(1):96-103. Epub 2015 Nov 18.
    View PubMed
  111. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Osterlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Kohne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litiere S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Oberg K, Palumbo A, Peccatori FA, Pfeilstocker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1 (5):e000097 Epub 2016 Sept 29
    View PubMed
  112. Majithia N, Grothey A. Regorafenib in the treatment of colorectal cancer. Expert Opin Pharmacother. 2016; 17 (1):137-45 Epub 2015 Dec 04
    View PubMed
  113. Coutinho A, Grothey A, Marshall JL. Adjuvant therapy after resection of metastatic colorectal cancer Oncology (08909091). 2016; 30: (1)50-3.
  114. Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argiles G, Adenis A, Ychou M, Barone C, Bouche O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). ESMO Open. 2016; 1 (6):e000111 Epub 2017 Feb 13
    View PubMed
  115. Grothey A, Marshall JL, Seery TE. Current options for third-line treatment of metastatic colorectal cancer: discussion Clinical Advances in Hematology and Oncology. 2016; 14: (3)13-4.
  116. An MW, Dong X, Meyers J, Han Y, Grothey A, Bogaerts J, Sargent DJ, Mandrekar SJ, Response Evaluation Criteria in Solid Tumors Steering Committee. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. J Natl Cancer Inst. 2015 Nov; 107 (11) Epub 2015 Aug 21
    View PubMed
  117. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015 Oct 20; 33 (30):3416-22 Epub 2015 Aug 17
    View PubMed
  118. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst. 2015 Oct; 107 (10) Epub 2015 Aug 01
    View PubMed
  119. Sargent DJ, Mandrekar S, Grothey A. Introduction to special issue on biomarker-based clinical trial designs in oncology. Chin Clin Oncol. 2015 Sep; 4: (3)28.
    View PubMed
  120. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw. 2015 Sep; 13 (9):1097-101
    View PubMed
  121. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015 Sep; 41 (8):653-9 Epub 2015 May 21
    View PubMed
  122. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug; 16 (8):937-48 Epub 2015 July 13
    View PubMed
  123. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13 (6):719-28; quiz 728
    View PubMed
  124. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A. Randomized phase iii trial of regorafenib in metastatic colorectal cancer: analysis of the correct japanese and non-japanese subpopulations. Invest New Drugs. 2015 Jun; 33(3):740-50.
    View PubMed
  125. Benson AB III, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal cancer, version 2.2015 featured updates to the nccn guidelines. J. Natl. Compr. Cancer Netw. 2015 Jun; 13(6):719-28.
  126. Renfro LA, Grothey A, Kerr D, Haller DG, Andre T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general populationdagger. Ann Oncol. 2015 May; 26 (5):950-958 Epub 2015 Feb 19
    View PubMed
  127. Grothey A. Optimizing systemic therapy selection in metastatic colorectal cancer. J Natl Compr Canc Netw. 2015 May; 13 (5 Suppl):682-5
    View PubMed
  128. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May; 16 (5):499-508 Epub 2015 Apr 12
    View PubMed
  129. Phuoc V, Grothey A. Metastatic extramammary Paget's disease responding to weekly paclitaxel. BMJ Case Rep. 2015 Apr 22; 2015
    View PubMed
  130. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12 (2):73-4 Epub 2015 Jan 06
    View PubMed
  131. Hubbard JM, Grothey A. Colorectal cancer in 2014 : Progress in defining first-line and maintenance therapies Nature Reviews Gastroenterology and Hepatology. 2015; 12: (1)19-20.
  132. Leal AD, Hubbard J, Sargent D, Grothey A. New adjuvant trial designs in colon cancer Current Colorectal Cancer Reports. 2015; 11: (6)326-34.
  133. Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA. Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag. 2015; 2 (2) Epub 2015 Apr 10
    View PubMed
  134. Yan Y, Grothey A. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther. 2015; 8:2949-57 Epub 2015 Oct 15
    View PubMed
  135. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159 Epub 2015 May 21
    View PubMed
  136. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Diaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015 Jan 1; 33 (1):22-8 Epub 2014 Nov 10
    View PubMed
  137. Renfro LA, Grothey A, Xue Y, Saltz LB, Andre T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Oct 29
    View PubMed
  138. Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23 (7):726-34 Epub 2014 May 16
    View PubMed
  139. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  140. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract. 2014 Jul; 10 (4):248-53 Epub 2014 Mar 25
    View PubMed
  141. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, ARIES Study Investigators. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26 (6):323-32 Epub 2014 Mar 28
    View PubMed
  142. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13 (2):100-9 Epub 2013 Dec 28
    View PubMed
  143. Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun; 19 (6):669-80 Epub 2014 May 12
    View PubMed
  144. Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014 Jun; 25 (6):1172-8 Epub 2014 Mar 07
    View PubMed
  145. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014 Apr 1; 32 (10):997-1005 Epub 2013 Dec 02
    View PubMed
  146. Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. J Clin Oncol. 2014 Mar 10; 32 (8):841-50 Epub 2014 Feb 10
    View PubMed
  147. Sridharan M, Hubbard JM, Grothey A. Colorectal cancer: how emerging molecular understanding affects treatment decisions. Oncology (Williston Park). 2014 Feb; 28 (2):110-8
    View PubMed
  148. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31 (6):1559-67 Epub 2013 Oct 10
    View PubMed
  149. Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013 Oct 10; 31 (29):3656-63 Epub 2013 Aug 26
    View PubMed
  150. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol. 2013 Oct; 10(10):571-87. Epub 2013 Sep 03.
    View PubMed
  151. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11 (10):1219-25
    View PubMed
  152. Cheville AL, Kollasch J, Vandenberg J, Shen T, Grothey A, Gamble G, Basford JR. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013 May; 45 (5):811-21 Epub 2012 Sept 24
    View PubMed
  153. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381 (9863):303-12 Epub 2012 Nov 22
    View PubMed
  154. Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ, for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9:261-9.
    View PubMed
  155. Clary BM, Grothey A, Kopetz S, Marsh RDW. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: Expert consensus statement. HPB. 2013; 15(2):116-8.
    View PubMed
  156. Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012 Nov; 4 (6):301-19
    View PubMed
  157. Warsame R, Grothey A. Treatment options for advanced pancreatic cancer: a review. Expert Rev Anticancer Ther. 2012 Oct; 12(10):1327-36.
    View PubMed
  158. Grothey A. Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2012 Jul; 10 (7 Suppl 9):1-24
    View PubMed
  159. Di Valentin, Alam Y, Ali Alsharm, Arif S, Aubin F, Biagi J, Booth CM, Bourque S, Burkes R, Champion P, Colwell B, Cripps C, Dallaire M, Dorreen M, Finn N, Frechette D, Gallinger S, Gapski J, Giacomantonio C, Gill S, Goel R, Goodwin R, Grimard L, Grothey A, Hammad N, Hedley D, Jhaveri K, Jonker D, Ko Y, L'esperance M, Maroun J, Ostic H, Perrin N, Rother M, St-Hilaire E, Tehfe M, Thirlwell M, Welch S, Yarom N, Asmis T. Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers. Curr Oncol. 2012 Jun; 19(3):169-74.
    View PubMed
  160. Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32. Epub 2012 Mar 15.
    View PubMed
  161. Grothey A. Regorafenib in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2012 May; 10(5):324-5.
    View PubMed
  162. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4; 307 (13):1383-93
    View PubMed
  163. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90. Epub 2011 Jul 28.
    View PubMed
  164. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20; 30 (3):263-7 Epub 2011 Dec 12
    View PubMed
  165. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18 (2):546-54
    View PubMed
  166. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17: (12)1486-95.
    View PubMed
  167. Grothey A. Optimal treatment strategies for localized and advanced microsatellite instability-high colorectal cancer. Current Colorectal Cancer Reports. 2012; 8(1):36-41.
  168. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist. 2012; 17 (5):725-31 Epub 2012 Apr 17
    View PubMed
  169. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. Epub 2011 Mar 01.
    View PubMed
  170. Gonsalves WI, Grothey A. Waiting in line for cancer treatments? Gastrointest Cancer Res. 2011 Jul; 4 (4):147-9
    View PubMed
  171. Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011 Jun; 13 (3):168-76
    View PubMed
  172. Van Cutsem, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de, Zalcberg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011 Jun; 22 Suppl 5:v1-9.
    View PubMed
  173. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A, Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011 May; 47 (7):990-6 Epub 2011 Jan 21
    View PubMed
  174. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011 Mar; 11(2):171-82.
    View PubMed
  175. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011 Feb 1; 29 (4):421-7 Epub 2010 Dec 28
    View PubMed
  176. Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ, NCI GI Steering Committee Colon Cancer Task Force. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist. 2011; 16 (8):1061-8 Epub 2011 July 07
    View PubMed
  177. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  178. Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011; 16 (6):859-67 Epub 2011 May 31
    View PubMed
  179. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 2011; 5:89-99 Epub 2011 Apr 25
    View PubMed
  180. Jordan K, Grothey A, Pelz T, Lautenschlager C, Franke U, Schober C, Schmoll HJ. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. Eur J Cancer Care (Engl). 2010 Sep; 19(5):603-9. Epub 2009 Aug 31.
    View PubMed
  181. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10; 28(20):3227-33. Epub 2010 Jun 07.
    View PubMed
  182. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10; 28 (20):3219-26 Epub 2010 May 24
    View PubMed
  183. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22 (4):374-80
    View PubMed
  184. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010 Jun; 7(6):309-17. Epub 2010 Apr 6.
    View PubMed
  185. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol. 2010 May 20; 28(15):2641-7. Epub 2010 Apr 20.
    View PubMed
  186. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010 Apr 10; 28 (11):1936-41 Epub 2010 Mar 08
    View PubMed
  187. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 2010 Mar-Apr; 16(2):125-31.
    View PubMed
  188. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46.
    View PubMed
  189. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  190. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39. Epub 2010 Aug 20.
    View PubMed
  191. Grothey A. My take: 'Remarkable' results present a quandary. Oncol. Rep.. 2010; (Jul-Aug)17.
  192. Van Cutsem, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de, Schmoll HJ, Sobrero A, Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol. 2010; 21(Suppl 6):1-10.
  193. Grothey A. Risk assessment in stage II colon cancer: to treat or not to treat? Oncology (Williston Park). 2010 Jan; 24(1 Suppl 1):1-2.
    View PubMed
  194. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3).
  195. Bennett GJ, Grothey A, Loprinzi CL. Peripheral neurotoxicities. J Support Oncol. 2010; 8(2, suppl 1):22-3.
  196. Grothey A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology. 2010; 79 (5-6):389-99 Epub 2011 Mar 25
    View PubMed
  197. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  198. Banck MS, Grothey A. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2009 Dec 15; 15 (24):7492-7501
    View PubMed
  199. Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer. 2009 Nov; 19(8):1446-53.
    View PubMed
  200. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70. Epub 2009 Sep 2
    View PubMed
  201. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009 Sep; 6 (9):507-18 Epub 2009 July 28
    View PubMed
  202. Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol. 2009 Sep; 1 (2):55-68
    View PubMed
  203. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1; 27(22):3677-83. Epub 2009 May 26.
    View PubMed
  204. Sargent DJ, Kohne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009 Apr 20; 27 (12):1948-55 Epub 2009 Mar 02
    View PubMed
  205. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20; 27 (6):872-7 Epub 2009 Jan 05
    View PubMed
  206. Wagner ADADW, Arnold D, Grothey AAG, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer (Review) - art. no. CD005392. Cochrane Database Syst Rev. 2009; (3):5392.
  207. Grothey A. Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. Current Colorectal Cancer Reports. 2009; 5(2):65-6.
  208. Turja J, Grothey A. Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1479-81.
    View PubMed
  209. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20; 26 (33):5326-34 Epub 2008 Oct 14
    View PubMed
  210. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35 (5):530-44
    View PubMed
  211. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res. 2008 Oct; 17(5):529-35. Epub 2008 Feb 19.
    View PubMed
  212. Grothey A. Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. Gastrointest Cancer Res. 2008 Sep; 2 (5):258-60
    View PubMed
  213. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008 Jul; 44 (11):1507-15 Epub 2008 June 18
    View PubMed
  214. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics. 2008 Jun; 2 (2):223-8
    View PubMed
  215. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008 May 10; 26(14):2336-41.
    View PubMed
  216. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther. 2008 May; 16 (5):979-84 Epub 2008 Mar 18
    View PubMed
  217. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008 May-Jun; 14(3):170-7.
    View PubMed
  218. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008 Jan 10; 26 (2):183-9
    View PubMed
  219. Grothey A, Arnold D, Ellis LM. Should bevacizumab be continued beyond progression in colorectal cancer? Current Colorectal Cancer Reports. 2008; 4(3):139-43.
  220. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R, AIO Colorectal Study Group. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Jan; 7(1):60-4.
    View PubMed
  221. Grothey A. The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biologic agents and conversion therapy. Community Oncol. 2008; 5(6 SUPPL. 6):3-8.
  222. Grothey A. Metastatic colorectal cancer: integrating recent findings into patient care. Clin Adv Hematol Oncol. 2008; 6(12, suppl 21):7-11.
  223. Grothey A. Biological therapy and other novel therapies in early-stage disease: are they appropriate? Clin Cancer Res. 2007 Nov 15; 13 (22 Pt 2):6909s-12s
    View PubMed
  224. Rosen LS, Bilchik AJ, Beart RW Jr, Benson AB 3rd, Chang KJ, Compton CC, Grothey A, Haller DG, Ko CY, Lynch PM, Nelson H, Stamos MJ, Turner RR, Willett CG. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 2):6853s-6s.
    View PubMed
  225. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A, ACCENT Group. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007 Oct 10; 25 (29):4569-74 Epub 2007 Sept 17
    View PubMed
  226. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007 Sep 20; 25(27):4217-23. Epub 2007 Jun 04.
    View PubMed
  227. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007 Sep; 15(9):1023-33. Epub 2007 Jan 05.
    View PubMed
  228. Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer. 2007 Aug 1; 110(3):670-7.
    View PubMed
  229. Grothey A. The Continuum of Care in Colorectal Cancer: Eliminating the Concept of Distinct Lines of Treatment. ASCO. 2007 Educational Book. 2007 Jun:224-8.
  230. Grothey A, Marshall JL. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology (Williston Park). 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8.
    View PubMed
  231. Loprinzi CL, Barton DL, Jatoi A, Sloan J, Martenson J, Steensma D, Rao R, Novotny P, Sood A, Grothey A, Minasian L, Windschitl H. Symptom control trials: a 20-year experience. J Support Oncol. 2007 Mar; 5(3):119-25, 128.
    View PubMed
  232. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 Jan; 12: (1)38-50.
    View PubMed
  233. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park). 2006 Dec; 20 (14 Suppl 10):21-8
    View PubMed
  234. Grothey A. Is there a third-line therapy for metastatic colorectal cancer? Semin Oncol. 2006 Dec; 33(6 Suppl 11):S36-8.
    View PubMed
  235. Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer. 2006 Nov; 6(4):261-4.
    View PubMed
  236. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct; 13(10):1261-8. Epub 2006 Sep 01.
    View PubMed
  237. Grothey A. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S41-9.
    View PubMed
  238. Gibson TB, Grothey A. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? Clin Colorectal Cancer. 2006 Sep; 6(3):196-201.
    View PubMed
  239. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20; 24(18):2903-9.
    View PubMed
  240. Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2006 Jun; 6 (6):921-30
    View PubMed
  241. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):29-31.
    View PubMed
  242. Grothey A. Defining the role of panitumumab in colorectal cancer. Community Oncol. 2006; 3(10 Suppl 4):10-4, 16.
  243. Grothey E, Grothey A. New treatment options for patients with metastatic colorectal cancer. Community Oncol. 2006; 3(10 Suppl 4):3-9.
  244. Grothey A. Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy? Nat Clin Pract Oncol. 2006 Jan; 3(1):22-3.
    View PubMed
  245. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1; 23(34):8664-70.
  246. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1; 23 (34):8664-70 Epub 2005 Oct 31
    View PubMed
  247. Kim GP, Grothey A. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. Clin Colorectal Cancer. 2005 Nov; 5 Suppl 2:S89-97
    View PubMed
  248. Grothey A, Saif M. Antiangiogenesis as antitumor therapy in gastrointestinal malignancies. Integrating Antiangiogenic Molecules in the Treatment of Patients With Cancer. 2005 Oct:10-21.
  249. Saif M, Grothey A. Antiangiogenesis as Antitumor Therapy in Nongastrointestinal Malignancies: Renal Cell, Lungs, and Breast. Integrating Antiangoiogenic Molecules in the Treatment of Patients With Cancer. 2005 Oct.:21-30.
  250. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5 (3):211-3
    View PubMed
  251. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug; 16(8):1311-9.
    View PubMed
  252. Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol. 2005 May 20; 23 (15):3311-3
    View PubMed
  253. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2005 Apr 18; 2:CD004064.
    View PubMed
  254. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005 Apr; 5 Suppl 1:S38-46
    View PubMed
  255. Grothey A, Kleeberg UR, Stauch M, Hieke K. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z Gastroenterol. 2005 Feb; 43(2):155-61.
    View PubMed
  256. Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherpy-induced emesis: a pooled analysis. Support Care Cancer. 2005; 13:26-31.
    View PubMed
  257. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ. Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. Eur J Haematol. 2005 Jan; 74:263-266.
    View PubMed
  258. Jordan K, Grothey A, Kegel T, Fibich C, Schobert C. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie. 2005 Jan; 28:88-92.
    View PubMed
  259. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics. 2005; 5 (5):317-25
    View PubMed
  260. Jackisch C, Grothey A, Schlotter CM, Mielke S, Wassmann KI, Behringer D, Mross K, Rody A. Practical aspects in the treatment of metastatic breast cancer with administration of paclitaxel weekly. Geburtsh Frauenheilk. 2004 Nov; 64(11):1199-1204.
  261. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004 Oct; 5 (10):2159-70
    View PubMed
  262. Hieke K, Kleeberg UR, Stauch M, Grothey A. Costs of treatment of colorectal cancer in different settings in Germany. European Journal of Health Economics. 2004 Oct; 5(3):270-3.
    View PubMed
  263. Goetz MP, Grothey A. Developments in combination chemotherapy for colorectal cancer. Expert Rev Anticancer Ther. 2004 Aug; 4 (4):627-37
    View PubMed
  264. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer. 2004 Jun; 4 Suppl 1:S37-42
    View PubMed
  265. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer. 2004 May; 4(1):46-50.
    View PubMed
  266. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 1; 22 (7):1209-14
    View PubMed
  267. Marse H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda((R))). Eur J Oncol Nurs. 2004; 8(3 Suppl):S16-30.
    View PubMed
  268. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003 Aug; 30(4 Suppl 15):5-13.
    View PubMed
  269. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 2003 Jan 15; 63(2):513-21.
    View PubMed
  270. Grothey A, Arnold D. Highlights in colorectal cancer. Onkologie heute. 2003; 1(2):10-4.
  271. Grothey A, Jordan K. Capecitabine/ oxaliplatin as first-line therapy in colorectal cancer - a case report. Case Studies in Colorectal Cancer. 2003; 2(3):1-8.
  272. Grothey A, Kellermann L, Schmoll HJ. [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms] [German]. Med Klin. 2002 May 15; 97(5):270-7.
    View PubMed
  273. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ. A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study. Onkologie. 2002 Apr; 25(2):158-64.
    View PubMed
  274. Grothey A, Graeven U. Colorectal cancer - new trials - new developments. Journal Med. 2002; 3:21-4.
  275. Grothey A, Graeven U. New developments in the treatment of advanced colorectal cancer. Journal Onkologie. 2002; 2(3):26-30.
  276. Grothey A, Dempke W. Current status of bisphoshonates in hematology and oncology. Internist prax. 2002; 42:291-9.
  277. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001 Jul; 127(7):411-7.
    View PubMed
  278. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol. 2001 Jul; 13(4):275-86.
    View PubMed
  279. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001 Apr; 12(4):435-42.
    View PubMed
  280. Fittkau M, Grothey A, Gerlach R, Schmoll HJ. A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J Cancer Res Clin Oncol. 2001 Feb; 127(2):96-100.
    View PubMed
  281. Koehne C, Grothey A, et al. Chemotherapy of the elderly patient with colorectal cancer. Arzneimitteltherapie. 2001; 19:377-85.
  282. Grothey A. Combination therapy with very good results in a phase III study in colorectal cancer. MedReview. 2001; 2:16-7.
  283. Grothey A. Prognostic and predictive factors in colorectal cancer. Journal Onkologie. 2001; 1:22-3.
  284. Grothey A. First-line therapy of advanced colorectal cancer. Journal Onkologie. 2001; 1:12-7.
  285. Grothey A. A typical cancer of the elderly - the colorectal carcinoma. Forum (Genova). 2001; 16: (5)42-7.
  286. Dempke W, Von Poblozki A, Grothey A, Schmoll HJ. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res. 2000 Nov-Dec; 20(6D):5155-64.
    View PubMed
  287. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW Jr, Yu D, Mooney EE, McCrea PD. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 5; 19(42):4864-75.
    View PubMed
  288. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer. 2000 Oct; 83(7):870-3.
    View PubMed
  289. Hasenburg A, Grothey A, Jaspers V, Gitsch G, Spatling L. Breast size as risk factor for tumor size at diagnosis. Anticancer Res. 2000 May-Jun; 20(3B):2041-4.
    View PubMed
  290. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res. 2000 May; 6(5):2087-93.
    View PubMed
  291. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes--a review. Anticancer Drugs. 2000 Apr; 11(4):225-36.
    View PubMed
  292. Kleber G, Grothey A. Hepatocellular carcinoma - epidemiology, laboratory, and prognosis. Onkologe. 2000; 6:292-300.
  293. Grothey A, Schmoll HJ. Systemic therapy of hepatocellular carcinoma. Onkologe. 2000; 6:327-35.
  294. Buechele T, Grothey A, et al. New perspectives with new cytostatic drugs in colorectal cancer. Onkologe. 2000; 6:410-9.
  295. Dempke W, Behrmann C, Schober C, Buchele T, Grothey A, Schmoll HJ. [Diagnostic and therapeutic management of the superior vena cava syndrome] [German]. Med Klin. 1999 Dec 15; 94(12):681-4.
    View PubMed
  296. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol. 1999 Dec; 26(6):589-605.
    View PubMed
  297. Dempke W, Voigt W, Grothey A, Schmoll HJ. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anticancer Drugs. 1999 Jul; 10(6):545-9.
    View PubMed
  298. Akimoto T, Kawabe S, Grothey A, Milas L. Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clin Exp Metastasis. 1999 Mar; 17(2):171-6.
    View PubMed
  299. Dempke W, Voigt W, Grothey A, Schmoll HJ. Option for high-dose chemotherapy in advanced gynecologic cancers. Gyn. 1999; 4:368-375.
  300. Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol. 1999; 125(3-4):166-73.
    View PubMed
  301. Buechele T, Grothey A, et al. New drugs in the treatment of colorectal cancer. Medizin im Bild. 1999; 2:50-5.
  302. Buechele T, Grothey A, et al. Adjuvant and palliative therapy of colorectal cancer. Spektrum Onkologie. 1999; 3:3-23.
  303. Grothey A, Duppe J, Hasenburg A, Voigtmann R. [Use of alternative medicine in oncology patients] [German]. Dtsch Med Wochenschr. 1998 Jul 31; 123(31-32):923-9.
    View PubMed
  304. Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs. 1998 Jun; 9(5):405-9.
    View PubMed
  305. Grothey A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer. 1998 Mar; 77(5):801-7.
    View PubMed
  306. Hasenburg A, Grothey A, et al. Current studies on cervical cancer in the USA. Onkologe. 1998; 4:180-4.
  307. Sanner B, Horstmann E, Heinze P, Kopp J, Grothey A. Successful rt-PA lysis of a transit thrombus in the right ventricle. Intensivmed. 1994; 31:447-451.
  308. Hasenburg A, Grothey A, et al. Clinical course and prognosis of patients under artificial respiration. Herz Kreislauf. 1992; 24:127-31.
  309. Donhuijsen K, Grothey A, Volker B, Dermoumi H. [Zygomycoses: clinical aspects and pathology in 10 patients] [German]. Schweiz Med Wochenschr. 1991 Oct 12; 121(41):1493-8.
    View PubMed
  310. Grothey A, Donhuijsen K. [Mucoraceae mycoses: clinical aspects and pathology in ten patients]. [German]. Mycoses. 1991; 34 Suppl 1:29-32.
    View PubMed
  311. Hoffken K, Overkamp F, Stirbu J, Grothey A, Flasshove M, Hoelzer D, Ganser A. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie. 1990 Feb; 13(1):33-7.
    View PubMed
  312. Franke I, Grothey A, Koch S, Witteler FJ, Binder M, Sandermann H Jr. N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization to the discriminative stimulus properties of delta 9-THC in rats. Biochem Pharmacol. 1985 Nov 15; 34(22):3983-6.
    View PubMed